10X: Moderna creates a billion-dose vaccine pact in a frenzied race to beat Covid-19 — globally
Forget what you’ve heard in recent weeks about millions, or even potentially hundreds of millions of doses of vaccines to be made in the near term to fight the pandemic. Today, the goal is set on the billion-dose mark, and Moderna $MRNA has moved the last manufacturing piece in place to hit the mark.
Early Friday the Boston-based mRNA player, which has the most advanced US vaccine in the clinic, announced a deal with Lonza creating a 10-year alliance on vaccine production, starting with mRNA-1287, headed into Phase II in a fast-paced trial program aimed at booting up a near-term approval that could land in a matter of months — roughly the R&D equivalent of taking a cross-country stock car race and powering the vehicles with rocket engines.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.